|
MechanismKRAS G12C inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Hangzhou Lingfang Biomedical Technology Co., Ltd.
0 Patents (Medical) associated with Hangzhou Lingfang Biomedical Technology Co., Ltd.
100 Deals associated with Hangzhou Lingfang Biomedical Technology Co., Ltd.
100 Translational Medicine associated with Hangzhou Lingfang Biomedical Technology Co., Ltd.